Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

O&G VivasGynaecological oncology — survivorship and MDT working

O&G Vivas · Gynaecological oncology — survivorship and MDT working

Survivorship and MDT working — structured oral station (12 minutes)

FRANZCOG oral-format station on gynaecological cancer survivorship: the candidate delivers the survivorship care plan, the sexual-function restorative ladder with dilator adherence, evidence-based surveillance reasoning, fear-of-recurrence management, and the structure and function of the gynaecological oncology MDT. Scored against the eight published RANZCOG oral domains.

clinical4 min readVerification in progress

Target exams

FRANZCOGMRCOGABOGFRCSCMRCPI
On this page
Study tools

Target exams

FRANZCOGMRCOGABOGFRCSCMRCPI
Prompt
You are the gynaecology registrar in a survivorship clinic. A 50-year-old woman is eleven months out from concurrent chemoradiotherapy for FIGO 2018 stage IIB cervical cancer. Her surveillance vault review, MRI and PET-CT are clear. She tells you, in tears, that intercourse is now too painful to continue, her left leg swells by the evening, her sleep is wrecked by hot flushes, and she is certain the cancer is coming back. The examiner will ask you to structure her survivorship care, manage her late effects, justify her surveillance, address her psychological distress, and describe how the multidisciplinary team supports her.

Station format

4 minutes reading, 12 minutes examination, 20 marks, global scoring. The eight published RANZCOG oral domains apply: history and examination; investigations and interpreting results; treatment and management; clinical knowledge; complex or unusual presentations; rapport; respect; communication. In a survivorship station, the rapport, respect and communication domains are where most candidates win or lose — this patient is frightened and vulnerable, and how you speak to her is scored. [1]

Reveal the examiner script and model responsesShowHide

Opening prompt — "Tell me how you structure this survivorship visit."

Model response — say it in this order: [1]

  • "I frame survivorship care as surveillance plus late-effect management plus psychosocial support, all documented in a survivorship care plan she and her GP hold. Today I will do four things: review for recurrence, screen for late effects, address her fear of recurrence, and update her plan."
  • "I will explicitly ask about sexual function, lymphoedema, menopause symptoms and mood — the four late effects that are commonest and most often missed."
  • "Her clear scans tell me this is a late-effect and psychosocial visit, not a recurrence visit — though I will keep new red-flag symptoms in mind."[1]

Examiner is listening for: the integrated framing, the four-domain screen, and the judgement that this is a late-effects visit, not a hunt for disease. [1]

Probe 1 — "She describes painful intercourse that has ended her relationship. Manage this."

  • "I would use permission-giving language first — 'Many women notice changes to their sexual health after this treatment' — because dysfunction is prevalent but under-reported unless invited."[2]
  • "The mechanism is radiotherapy-induced atrophy and fibrosis: the vagina shortens, narrows and loses lubrication. My ladder is non-hormonal first — a moisturiser for atrophy and a lubricant for activity — then topical vaginal oestrogen, which was studied in a randomised trial of dilator and topical agents for stenosis prevention after cervical radiotherapy."[3]
  • "Then vaginal dilator therapy, started now, used several times a week and long-term — and I know from the Law prospective study that adherence is the rate-limiting step, so I prescribe it with active support, not just a leaflet. I would add pelvic floor physiotherapy for hypertonicity and offer sex therapy."[4]

Probe 2 — "She asks why she must keep coming for pelvic exams when her scans are normal. What is the evidence?"

  • "I would be honest. In ovarian cancer, a retrospective series found most patients were asymptomatic when recurrence was detected, and the pelvic exam was not the primary means of detection — the authors argue the utility of routine visits and the pelvic exam should be re-examined."[5]
  • "In early endometrial cancer, a randomised trial showed patient-initiated follow-up was feasible and cost-reducing, with hospital visits easing fear of recurrence a little more."
  • "So for her — cervical cancer — the vault review has a role because local recurrence is often visible and salvageable, but the value of the visit is the symptom review, the late-effect review and the fear-of-recurrence conversation, not the exam alone."[5]

Probe 3 — "She is certain the cancer is returning. Address this."

This is a scored communication and rapport domain — demonstrate it out loud: [6]

  • "I would name it: fear of cancer recurrence is near-universal and it is the single biggest driver of surveillance demand. No number of normal scans will fix the underlying fear."
  • "I would screen her with the Distress Thermometer — paired with the Impact Thermometer — as a brief check for adjustment disorder or major depression, and treat a positive screen with structured psychological assessment."[6]
  • "Then I would give her a specific, written re-presentation plan: 'If you get new vaginal bleeding, constant pelvic pain, blood in your urine, or a swollen leg, call us — don't wait for your next appointment.' Converting dread into a sentence she can act on is the intervention."[6]

Probe 4 — "She is frightened and tearful. Speak to her."

  • Move to her eye level, use her name, acknowledge the fear plainly: "What you are feeling is very common after this treatment, and it does not mean the cancer is back. Your scans are clear. I want us to spend today on the parts of recovery that are hurting you — your relationship, your sleep, your worry — because those are treatable, and you deserve help with them."
  • Avoid jargon, avoid dismissing, do not conduct the conversation with your back turned, and commit to follow-up.[6]

Probe 5 — "How does the multidisciplinary team support her?"

  • "Every new and recurrent gynaecological cancer patient is discussed at the MDT, which the European Cancer Organisation makes the structural backbone of care — producing a documented, individualised treatment and survivorship plan."[7]
  • "The team is gynaecological oncology surgeons, medical and radiation oncologists, radiologists, pathologists, specialist cancer nurses, allied health — lymphoedema and pelvic floor physiotherapy — psycho-oncology, and for the survivorship phase, primary care. For her specifically I would activate the lymphoedema service for her leg, the physiotherapist for her pelvic floor, and psycho-oncology for her fear of recurrence."[7]
Obstetrics & Gynaecology Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship library.

Sign in to continueSee pricing
References7ShowHide
  1. [1]Mayer DK, Nekhlyudov L, Snyder CF, et al. American Society of Clinical Oncology clinical expert statement on cancer survivorship care planning J Oncol Pract, 2014.PMID 25316025
  2. [2]Hathout L, Zhang Y, Lymberis S, et al. A Systematic Review of Patient-Reported Outcomes on the Impact of Radiation Therapy on Sexual Health in Patients With Gynecologic Cancer Int J Radiat Oncol Biol Phys, 2026.PMID 41720168
  3. [3]Martins J, Vaz AF, Grion RC, et al. Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial BMC Cancer, 2021.PMID 34112100
  4. [4]Law E, Kelvin JF, Thom B, et al. Prospective study of vaginal dilator use adherence and efficacy following radiotherapy Radiother Oncol, 2015.PMID 26164775
  5. [5]Holtzman S, Gellman C, Chess I, et al. Surveillance Visits for Ovarian Cancer: Is It Time to Reconsider? J Surg Oncol, 2025.PMID 40990395
  6. [6]Akizuki N, Yamawaki S, Akechi T, et al. Development of an Impact Thermometer for use in combination with the Distress Thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients J Pain Symptom Manage, 2005.PMID 15652442
  7. [7]Sessa C, Travado L, Calaminus G, et al. European Cancer Organisation Essential Requirements for Quality Cancer Care for ovarian cancer: Focus on the multidisciplinary team Tumori, 2025.PMID 39643948
Obstetrics & Gynaecology Pro

$29/ monthor $279 / year

The complete Obstetrics & Gynaecology library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousSurgical positioning and nerve injuries — structured oral station (12 minutes)Perioperative care — positioning and nerve injuriesNextSurvivorship, MDT working and the generalist's role — structured oral station (12 minutes)Gynaecological oncology — survivorship